Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
AMYLOID
Study Name: ION-682884-CS2 (Amyloid)
Study Objective: A Phase 3 Global, Double-Blind, Randomized, Placebo‑Controlled
Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin‑Mediated Amyloid Cardiomyopathy (ATTR CM)
Key Inclusion Criteria:
A) prior hospitalization for HF, which may include hospitalization for arrhythmia or pacemaker/ICD (implantable cardioverter defibrillator) placement, OR
B) symptoms and signs of volume overload or elevated intracardiac pressure that either requires or required treatment with diuretics for clinical stabilization
Key Exclusion Criteria:
4 weeks prior to or during Screening
completed prior to Study Day 1
PI: Parag Goyal, MD (646) 962 5555
RC: Astrid Carmona (212) 746 2623